Max Wohlauer
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Surgical Procedures | 18 | 2024 | 343 | 3.540 |
Why?
| | Endovascular Procedures | 9 | 2024 | 385 | 1.650 |
Why?
| | Thrombosis | 3 | 2025 | 396 | 1.420 |
Why?
| | Peripheral Arterial Disease | 5 | 2025 | 504 | 1.210 |
Why?
| | Ischemia | 7 | 2025 | 422 | 1.160 |
Why?
| | Blood Coagulation Disorders | 10 | 2016 | 196 | 1.110 |
Why?
| | Surgeons | 7 | 2024 | 341 | 1.110 |
Why?
| | Arterial Occlusive Diseases | 2 | 2025 | 90 | 1.040 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2022 | 228 | 1.010 |
Why?
| | Shock, Hemorrhagic | 10 | 2024 | 202 | 0.970 |
Why?
| | Thrombelastography | 13 | 2020 | 190 | 0.960 |
Why?
| | Vascular System Injuries | 3 | 2023 | 78 | 0.940 |
Why?
| | Acute Lung Injury | 8 | 2015 | 301 | 0.940 |
Why?
| | Elective Surgical Procedures | 3 | 2024 | 201 | 0.880 |
Why?
| | Baseball | 1 | 2025 | 57 | 0.850 |
Why?
| | Aortic Aneurysm, Abdominal | 4 | 2022 | 167 | 0.840 |
Why?
| | Extremities | 1 | 2025 | 140 | 0.840 |
Why?
| | Brachial Artery | 1 | 2025 | 206 | 0.810 |
Why?
| | Leg Injuries | 1 | 2023 | 25 | 0.760 |
Why?
| | Wounds and Injuries | 13 | 2016 | 960 | 0.760 |
Why?
| | Intermittent Claudication | 2 | 2022 | 122 | 0.750 |
Why?
| | Diabetic Foot | 1 | 2022 | 25 | 0.750 |
Why?
| | Burnout, Professional | 4 | 2021 | 483 | 0.700 |
Why?
| | Ergonomics | 2 | 2026 | 29 | 0.700 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 387 | 0.650 |
Why?
| | Coronavirus Infections | 3 | 2020 | 381 | 0.650 |
Why?
| | Blood Transfusion | 8 | 2016 | 405 | 0.650 |
Why?
| | Sexism | 1 | 2021 | 69 | 0.650 |
Why?
| | Mental Health | 3 | 2022 | 792 | 0.630 |
Why?
| | Proteomics | 4 | 2025 | 1183 | 0.630 |
Why?
| | Cultural Diversity | 1 | 2021 | 85 | 0.630 |
Why?
| | Aortic Aneurysm, Thoracic | 3 | 2017 | 138 | 0.620 |
Why?
| | Musculoskeletal Pain | 1 | 2020 | 44 | 0.620 |
Why?
| | Aggression | 1 | 2021 | 178 | 0.610 |
Why?
| | Multiple Organ Failure | 4 | 2013 | 119 | 0.600 |
Why?
| | Muscle Fatigue | 1 | 2020 | 97 | 0.600 |
Why?
| | Foot | 1 | 2020 | 101 | 0.580 |
Why?
| | Internship and Residency | 4 | 2020 | 1262 | 0.580 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 293 | 0.580 |
Why?
| | Pandemics | 8 | 2023 | 1700 | 0.570 |
Why?
| | Tendons | 1 | 2020 | 129 | 0.570 |
Why?
| | Racism | 1 | 2021 | 155 | 0.570 |
Why?
| | Betacoronavirus | 3 | 2020 | 286 | 0.570 |
Why?
| | Axillary Artery | 2 | 2015 | 13 | 0.560 |
Why?
| | Occupational Diseases | 1 | 2020 | 165 | 0.560 |
Why?
| | Lymph | 3 | 2015 | 31 | 0.550 |
Why?
| | Running | 1 | 2020 | 230 | 0.520 |
Why?
| | Serum Albumin, Human | 1 | 2017 | 6 | 0.520 |
Why?
| | Vascular Diseases | 1 | 2020 | 252 | 0.510 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 27 | 0.510 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1180 | 0.490 |
Why?
| | Research Design | 1 | 2022 | 1129 | 0.480 |
Why?
| | Curriculum | 3 | 2019 | 1063 | 0.460 |
Why?
| | Blood Platelet Disorders | 2 | 2013 | 10 | 0.460 |
Why?
| | Axilla | 1 | 2015 | 51 | 0.450 |
Why?
| | Humans | 68 | 2026 | 144667 | 0.440 |
Why?
| | Aneurysm, False | 1 | 2015 | 45 | 0.440 |
Why?
| | Osteosarcoma | 1 | 2015 | 76 | 0.430 |
Why?
| | Treatment Outcome | 20 | 2025 | 11735 | 0.430 |
Why?
| | Fibrinolysis | 4 | 2025 | 164 | 0.430 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 128 | 0.410 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1076 | 0.410 |
Why?
| | Male | 44 | 2025 | 72431 | 0.380 |
Why?
| | Bone Neoplasms | 1 | 2015 | 255 | 0.380 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.370 |
Why?
| | Neutrophils | 4 | 2015 | 1118 | 0.370 |
Why?
| | Physicians | 1 | 2021 | 949 | 0.370 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 43 | 0.370 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1406 | 0.370 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2012 | 28 | 0.360 |
Why?
| | Acute Disease | 6 | 2025 | 1029 | 0.360 |
Why?
| | Duodenal Neoplasms | 1 | 2012 | 26 | 0.360 |
Why?
| | Carcinoma, Papillary | 1 | 2013 | 77 | 0.360 |
Why?
| | Ampulla of Vater | 1 | 2012 | 40 | 0.360 |
Why?
| | Pancreatic Ducts | 1 | 2013 | 81 | 0.360 |
Why?
| | Patient Handoff | 1 | 2012 | 43 | 0.360 |
Why?
| | Colonic Diseases | 1 | 2012 | 36 | 0.360 |
Why?
| | Decompression, Surgical | 2 | 2025 | 116 | 0.360 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2012 | 98 | 0.360 |
Why?
| | Workload | 4 | 2026 | 167 | 0.360 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2012 | 58 | 0.360 |
Why?
| | Intestinal Volvulus | 1 | 2012 | 23 | 0.360 |
Why?
| | Blood Coagulation | 5 | 2021 | 268 | 0.350 |
Why?
| | Hemodilution | 1 | 2011 | 11 | 0.340 |
Why?
| | Wounds, Penetrating | 1 | 2012 | 72 | 0.340 |
Why?
| | Multiple Trauma | 1 | 2012 | 121 | 0.330 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.330 |
Why?
| | Female | 40 | 2025 | 78304 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2521 | 0.310 |
Why?
| | Time-to-Treatment | 2 | 2024 | 242 | 0.310 |
Why?
| | General Surgery | 1 | 2012 | 206 | 0.310 |
Why?
| | Wounds, Nonpenetrating | 2 | 2015 | 321 | 0.300 |
Why?
| | Mesentery | 4 | 2015 | 44 | 0.300 |
Why?
| | Patient Transfer | 1 | 2012 | 208 | 0.290 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 294 | 0.290 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2024 | 299 | 0.290 |
Why?
| | Resuscitation | 3 | 2024 | 310 | 0.280 |
Why?
| | Risk Assessment | 9 | 2021 | 3729 | 0.270 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2022 | 496 | 0.270 |
Why?
| | Adult | 27 | 2025 | 40489 | 0.260 |
Why?
| | Thrombophilia | 2 | 2021 | 89 | 0.260 |
Why?
| | Time Factors | 9 | 2025 | 7140 | 0.260 |
Why?
| | Risk Factors | 10 | 2025 | 10796 | 0.250 |
Why?
| | Computer Simulation | 1 | 2011 | 1021 | 0.240 |
Why?
| | Rats | 8 | 2014 | 5570 | 0.240 |
Why?
| | Personnel Turnover | 1 | 2026 | 41 | 0.240 |
Why?
| | Blood Platelets | 4 | 2014 | 379 | 0.240 |
Why?
| | Anticoagulants | 4 | 2021 | 729 | 0.230 |
Why?
| | Median Arcuate Ligament Syndrome | 1 | 2025 | 8 | 0.230 |
Why?
| | Software | 1 | 2011 | 695 | 0.230 |
Why?
| | Celiac Artery | 1 | 2025 | 20 | 0.230 |
Why?
| | Middle Aged | 23 | 2025 | 35971 | 0.230 |
Why?
| | Retrospective Studies | 10 | 2025 | 17149 | 0.220 |
Why?
| | Balloon Occlusion | 2 | 2024 | 39 | 0.220 |
Why?
| | Adaptation, Psychological | 2 | 2021 | 718 | 0.220 |
Why?
| | Adenocarcinoma | 1 | 2012 | 923 | 0.220 |
Why?
| | Aged | 12 | 2025 | 25955 | 0.220 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1501 | 0.220 |
Why?
| | Hospitals, Public | 1 | 2025 | 30 | 0.220 |
Why?
| | Prospective Studies | 9 | 2022 | 7994 | 0.220 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 562 | 0.220 |
Why?
| | Angiography | 2 | 2023 | 208 | 0.210 |
Why?
| | Thrombectomy | 1 | 2025 | 78 | 0.210 |
Why?
| | Lower Extremity | 3 | 2023 | 440 | 0.210 |
Why?
| | Health Surveys | 3 | 2021 | 517 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2013 | 926 | 0.210 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.210 |
Why?
| | Nurses | 1 | 2026 | 168 | 0.200 |
Why?
| | Kidney | 1 | 2012 | 1495 | 0.200 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 326 | 0.200 |
Why?
| | Injury Severity Score | 7 | 2016 | 602 | 0.200 |
Why?
| | Brain Injuries | 3 | 2014 | 506 | 0.200 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2014 | 36 | 0.200 |
Why?
| | Occupational Health | 3 | 2021 | 210 | 0.200 |
Why?
| | Patient Care Team | 2 | 2024 | 690 | 0.190 |
Why?
| | Pain | 2 | 2026 | 785 | 0.190 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 60 | 0.190 |
Why?
| | Arachidonic Acid | 2 | 2014 | 101 | 0.190 |
Why?
| | Robotic Surgical Procedures | 1 | 2025 | 183 | 0.190 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 589 | 0.180 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.180 |
Why?
| | Hospital Mortality | 2 | 2021 | 1033 | 0.180 |
Why?
| | Specialties, Surgical | 2 | 2020 | 82 | 0.180 |
Why?
| | Blood Coagulation Tests | 2 | 2020 | 69 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2023 | 102 | 0.180 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 131 | 0.180 |
Why?
| | Iliac Aneurysm | 1 | 2022 | 19 | 0.180 |
Why?
| | Prevalence | 3 | 2020 | 2839 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 241 | 0.180 |
Why?
| | Peripheral Vascular Diseases | 1 | 2022 | 104 | 0.170 |
Why?
| | United States | 10 | 2024 | 16018 | 0.170 |
Why?
| | Arteriovenous Fistula | 1 | 2021 | 38 | 0.170 |
Why?
| | Aortic Rupture | 1 | 2021 | 27 | 0.170 |
Why?
| | Point-of-Care Systems | 3 | 2012 | 188 | 0.170 |
Why?
| | Aorta | 1 | 2024 | 427 | 0.170 |
Why?
| | Iliac Vein | 1 | 2021 | 15 | 0.170 |
Why?
| | Work Capacity Evaluation | 1 | 2020 | 11 | 0.160 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.160 |
Why?
| | Culturally Competent Care | 1 | 2021 | 73 | 0.160 |
Why?
| | Vena Cava, Inferior | 1 | 2021 | 81 | 0.160 |
Why?
| | Tenotomy | 1 | 2020 | 22 | 0.160 |
Why?
| | Surveys and Questionnaires | 8 | 2026 | 6041 | 0.160 |
Why?
| | Physicians, Women | 1 | 2021 | 88 | 0.160 |
Why?
| | Tendon Transfer | 1 | 2020 | 24 | 0.160 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 73 | 0.150 |
Why?
| | International Cooperation | 1 | 2020 | 197 | 0.150 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 120 | 0.150 |
Why?
| | Posture | 1 | 2020 | 197 | 0.150 |
Why?
| | Thromboembolism | 1 | 2020 | 126 | 0.150 |
Why?
| | Partnership Practice | 1 | 2018 | 3 | 0.150 |
Why?
| | Societies, Medical | 2 | 2020 | 890 | 0.140 |
Why?
| | Insurance Benefits | 1 | 2018 | 12 | 0.140 |
Why?
| | Venous Thrombosis | 1 | 2021 | 193 | 0.140 |
Why?
| | Mentors | 1 | 2021 | 214 | 0.140 |
Why?
| | Infection Control | 1 | 2020 | 174 | 0.140 |
Why?
| | Physical Endurance | 1 | 2020 | 274 | 0.140 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 124 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 276 | 0.140 |
Why?
| | Medically Uninsured | 1 | 2018 | 129 | 0.130 |
Why?
| | Pain Measurement | 1 | 2020 | 554 | 0.130 |
Why?
| | Walking | 1 | 2022 | 542 | 0.130 |
Why?
| | Triage | 1 | 2020 | 249 | 0.130 |
Why?
| | Statistics, Nonparametric | 3 | 2014 | 427 | 0.130 |
Why?
| | Insurance Coverage | 1 | 2018 | 243 | 0.120 |
Why?
| | Nutrition Assessment | 1 | 2017 | 92 | 0.120 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 852 | 0.120 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2014 | 71 | 0.120 |
Why?
| | Chronic Disease | 3 | 2024 | 1810 | 0.120 |
Why?
| | Registries | 2 | 2024 | 2392 | 0.120 |
Why?
| | Insurance, Health | 1 | 2018 | 308 | 0.120 |
Why?
| | Hemostatic Techniques | 1 | 2016 | 52 | 0.120 |
Why?
| | Receptor, PAR-2 | 1 | 2015 | 6 | 0.110 |
Why?
| | Recovery of Function | 1 | 2020 | 715 | 0.110 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2015 | 26 | 0.110 |
Why?
| | Motor Activity | 1 | 2020 | 723 | 0.110 |
Why?
| | Exsanguination | 2 | 2012 | 19 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1569 | 0.110 |
Why?
| | Plasminogen | 1 | 2015 | 27 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1360 | 0.110 |
Why?
| | Sex Factors | 1 | 2021 | 2104 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8284 | 0.110 |
Why?
| | Geriatric Assessment | 1 | 2017 | 233 | 0.110 |
Why?
| | Postoperative Complications | 3 | 2025 | 2950 | 0.110 |
Why?
| | Cohort Studies | 3 | 2022 | 5957 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1209 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 95 | 0.110 |
Why?
| | Microcirculation | 1 | 2015 | 141 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 616 | 0.110 |
Why?
| | Biomedical Research | 1 | 2021 | 712 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 967 | 0.110 |
Why?
| | Medicaid | 1 | 2018 | 464 | 0.100 |
Why?
| | Blood Vessel Prosthesis | 3 | 2022 | 140 | 0.100 |
Why?
| | Thrombin | 2 | 2015 | 167 | 0.100 |
Why?
| | Odds Ratio | 1 | 2017 | 1076 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1262 | 0.100 |
Why?
| | Animals | 10 | 2015 | 37948 | 0.100 |
Why?
| | Chi-Square Distribution | 2 | 2012 | 524 | 0.100 |
Why?
| | Frailty | 1 | 2017 | 200 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1322 | 0.100 |
Why?
| | Limb Salvage | 2 | 2025 | 73 | 0.100 |
Why?
| | Subclavian Artery | 1 | 2013 | 28 | 0.100 |
Why?
| | Carotid Artery, Common | 1 | 2013 | 31 | 0.100 |
Why?
| | Prosthesis Design | 3 | 2022 | 355 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 630 | 0.090 |
Why?
| | History, 17th Century | 1 | 2012 | 14 | 0.090 |
Why?
| | History, 18th Century | 1 | 2012 | 18 | 0.090 |
Why?
| | Medicare | 1 | 2018 | 899 | 0.090 |
Why?
| | Fibrinogen | 1 | 2014 | 181 | 0.090 |
Why?
| | Brazil | 2 | 2025 | 182 | 0.090 |
Why?
| | Comorbidity | 2 | 2021 | 1652 | 0.090 |
Why?
| | History, 19th Century | 1 | 2012 | 63 | 0.090 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 62 | 0.090 |
Why?
| | Sigmoid Diseases | 1 | 2012 | 14 | 0.090 |
Why?
| | Social Responsibility | 1 | 2012 | 53 | 0.090 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 37 | 0.090 |
Why?
| | Colorado | 5 | 2016 | 4558 | 0.090 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 104 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1788 | 0.090 |
Why?
| | Isoflurane | 1 | 2012 | 41 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2012 | 184 | 0.090 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2011 | 5 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 18 | 0.090 |
Why?
| | Anesthetics, Inhalation | 1 | 2012 | 52 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1148 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2012 | 115 | 0.090 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2011 | 35 | 0.090 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1537 | 0.090 |
Why?
| | Social Values | 1 | 2012 | 42 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2012 | 140 | 0.090 |
Why?
| | Random Allocation | 1 | 2012 | 366 | 0.090 |
Why?
| | Narration | 1 | 2012 | 78 | 0.090 |
Why?
| | Colectomy | 1 | 2012 | 106 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2012 | 156 | 0.090 |
Why?
| | Extravascular Lung Water | 1 | 2011 | 9 | 0.090 |
Why?
| | Renal Replacement Therapy | 1 | 2012 | 99 | 0.080 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2011 | 33 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 327 | 0.080 |
Why?
| | Survival Rate | 2 | 2016 | 2089 | 0.080 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 83 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2012 | 570 | 0.080 |
Why?
| | Abdominal Pain | 1 | 2012 | 147 | 0.080 |
Why?
| | Abdominal Injuries | 1 | 2012 | 130 | 0.080 |
Why?
| | Depression | 1 | 2020 | 1561 | 0.080 |
Why?
| | Oxidative Stress | 3 | 2014 | 1338 | 0.080 |
Why?
| | Health Care Surveys | 2 | 2024 | 537 | 0.080 |
Why?
| | Hypothermia | 1 | 2011 | 52 | 0.080 |
Why?
| | Efficiency | 1 | 2011 | 104 | 0.080 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 341 | 0.080 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 285 | 0.080 |
Why?
| | Superoxides | 1 | 2011 | 199 | 0.080 |
Why?
| | Adolescent | 6 | 2025 | 22409 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 275 | 0.080 |
Why?
| | Acidosis | 1 | 2011 | 105 | 0.080 |
Why?
| | Trauma Centers | 4 | 2016 | 466 | 0.080 |
Why?
| | Biomarkers | 3 | 2017 | 4261 | 0.080 |
Why?
| | Proteome | 1 | 2014 | 515 | 0.080 |
Why?
| | Pancreatectomy | 1 | 2013 | 286 | 0.080 |
Why?
| | Logistic Models | 2 | 2012 | 2114 | 0.070 |
Why?
| | Models, Animal | 1 | 2011 | 393 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2015 | 864 | 0.070 |
Why?
| | Safety | 1 | 2011 | 356 | 0.070 |
Why?
| | Recurrence | 1 | 2012 | 1136 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 5870 | 0.070 |
Why?
| | Quality Improvement | 2 | 2021 | 1287 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1705 | 0.070 |
Why?
| | Reperfusion Injury | 1 | 2011 | 296 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 501 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4539 | 0.070 |
Why?
| | Tissue and Organ Procurement | 1 | 2012 | 341 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1995 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 732 | 0.060 |
Why?
| | Lung | 3 | 2015 | 4089 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2014 | 444 | 0.060 |
Why?
| | Prognosis | 2 | 2013 | 4312 | 0.060 |
Why?
| | Communication | 1 | 2012 | 972 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 565 | 0.060 |
Why?
| | Embolectomy | 1 | 2025 | 13 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2892 | 0.050 |
Why?
| | Operative Time | 1 | 2025 | 181 | 0.050 |
Why?
| | Young Adult | 6 | 2025 | 14122 | 0.050 |
Why?
| | Databases, Factual | 2 | 2021 | 1494 | 0.050 |
Why?
| | Platelet Function Tests | 2 | 2014 | 35 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2012 | 1176 | 0.050 |
Why?
| | Clinical Competence | 1 | 2012 | 1237 | 0.050 |
Why?
| | Aortography | 2 | 2013 | 52 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2024 | 200 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3414 | 0.050 |
Why?
| | Receptors, Purinergic P2 | 2 | 2013 | 23 | 0.050 |
Why?
| | Platelet Activation | 2 | 2014 | 98 | 0.050 |
Why?
| | Mesenteric Artery, Inferior | 1 | 2022 | 2 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 207 | 0.040 |
Why?
| | Iliac Artery | 1 | 2022 | 55 | 0.040 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.040 |
Why?
| | Product Labeling | 1 | 2021 | 11 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2024 | 464 | 0.040 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 262 | 0.040 |
Why?
| | Phlebography | 1 | 2021 | 41 | 0.040 |
Why?
| | Depersonalization | 1 | 2020 | 7 | 0.040 |
Why?
| | Blood Component Transfusion | 2 | 2012 | 104 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 99 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2754 | 0.040 |
Why?
| | Work-Life Balance | 1 | 2020 | 22 | 0.040 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 10 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2022 | 268 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2020 | 52 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 57 | 0.040 |
Why?
| | Heparin | 1 | 2021 | 243 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 92 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 402 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 2019 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 539 | 0.030 |
Why?
| | Popliteal Artery | 1 | 2018 | 62 | 0.030 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 103 | 0.030 |
Why?
| | Stents | 1 | 2022 | 557 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 360 | 0.030 |
Why?
| | Hemorrhage | 1 | 2022 | 813 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 369 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 401 | 0.030 |
Why?
| | Career Choice | 1 | 2019 | 233 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 586 | 0.030 |
Why?
| | Military Personnel | 1 | 2024 | 733 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1056 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 465 | 0.030 |
Why?
| | Alarmins | 1 | 2015 | 27 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2015 | 52 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 578 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 129 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3603 | 0.030 |
Why?
| | Tranexamic Acid | 1 | 2015 | 55 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 915 | 0.030 |
Why?
| | Mesenteric Artery, Superior | 1 | 2013 | 28 | 0.030 |
Why?
| | Renal Artery | 1 | 2013 | 43 | 0.020 |
Why?
| | Inflammation | 2 | 2015 | 2870 | 0.020 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 156 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2014 | 516 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 218 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3329 | 0.020 |
Why?
| | Platelet Count | 1 | 2013 | 94 | 0.020 |
Why?
| | Blood Proteins | 1 | 2014 | 230 | 0.020 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.020 |
Why?
| | Leukotriene C4 | 1 | 2012 | 6 | 0.020 |
Why?
| | Chlorobenzenes | 1 | 2012 | 18 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 794 | 0.020 |
Why?
| | Leukotriene B4 | 1 | 2012 | 37 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 161 | 0.020 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 34 | 0.020 |
Why?
| | Ticlopidine | 1 | 2012 | 51 | 0.020 |
Why?
| | Eicosanoids | 1 | 2012 | 58 | 0.020 |
Why?
| | Peroxidase | 1 | 2012 | 167 | 0.020 |
Why?
| | Cell Membrane | 1 | 2015 | 706 | 0.020 |
Why?
| | Dinoprostone | 1 | 2012 | 180 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 364 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1154 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 743 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2011 | 66 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1078 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 324 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2013 | 289 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1098 | 0.020 |
Why?
| | Waiting Lists | 1 | 2012 | 263 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3183 | 0.020 |
Why?
| | Hemolysis | 1 | 2011 | 242 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 496 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 504 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2184 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2011 | 733 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2011 | 4110 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5414 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5967 | 0.010 |
Why?
| | Mice | 1 | 2012 | 18261 | 0.010 |
Why?
|
|
Wohlauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|